metricas
covid
Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Differences in the diabetogenic effect of statins in patients with prediabetes. ...
Journal Information
Vol. 158. Issue 11.
Pages 531-539 (June 2022)
Share
Share
Download PDF
More article options
Visits
18
Vol. 158. Issue 11.
Pages 531-539 (June 2022)
Original article
Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study
Diferencias en cuanto al efecto diabetógeno de las estatinas en pacientes con prediabetes. Estudio Prelipid
Visits
18
Ferran Triasa,b, Xavier Pintóa,b,c,d,
Corresponding author
xpinto@bellvitgehospital.cat

Corresponding author.
, Emili Corbellaa,b,c, Manuel Suárez-Tembrae, Antonio Ruíz-Garcíaf, José Luis Díaz-Díazg, Elena Sánchez-Ruíz-Granadoh, Itziar Sarasaa,b, Raul Martínez-Porquerasa,i, Maria Angeles Rodríguez-Sáncheza,b, Xavier Corbellaa,j, on behalf of the PRELIPID Study Group 1
a Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario de Bellvitge-Idibell, Spain
b Fundación para la Investigación y Prevención de Enfermedades Cardiovasculares (FIPEC), Spain
c Centro de Investigación Biomédica en Red, Fisiopatologia de la Obesidad y Nutrición CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
d Facultad de Medicina, Universidad de Barcelona, Spain
e Unidad de Lipidos y Riesgo Cardiovascular, Hospital San Rafael, A Coruña, Spain
f Centro de Salud Universitario Pinto, Unidad de Lípidos y Prevención Cardiovascular, Pinto, Madrid, Spain
g Unidad de Lípidos y Riesgo Cardiovascular, Complejo Hospitalario Universitario, A Coruña, Spain
h Hospital Infanta Elena, Huelva, Spain
i Hospital Universitario 12 de Octubre, Madrid, Spain
j Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain
Ver más
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Patient characteristics according to statin treatment.
Table 2. Biochemical profile of patients according to statin treatment.
Table 3. Description of other treatments by statin treatment group.
Show moreShow less
Abstract
Introduction

Statins are used with the understanding that a slightly increased risk of diabetes is outweighed by their cardiovascular benefits. However, it may be necessary to reconsider whether statin therapy really increase this risk mainly in the population with prediabetes.

Methods

A multicenter, cross-sectional, observational study was conducted to assess the relationship between statin therapy and glucose metabolism in 407 patients aged 63.1 years (11SD) diagnosed with dyslipidemia and prediabetes treated in specialized lipid clinics in Spain.

Results

Significant differences were found in HbA1c values among treatment groups (p=0.015). Patients treated with pitavastatin (1–4mg/day) showed the lowest HbA1c levels, with significant differences compared to patients treated with atorvastatin 40–80mg/day (p=0.016) and simvastatin 10–40mg/day (p=0.036). By contrast, patients treated with atorvastatin 40–80mg/day showed the highest HbA1c levels compared to those receiving atorvastatin 10–20mg/day (p=0.003), pitavastatin 1–4mg/day (p=0.016), pravastatin 20–40mg/day (p=0.027), rosuvastatin 5–10mg/day (p=0.043), and no statin treatment (p=0.004). Patients treated with simvastatin 10–40mg/day also had higher values than those treated with atorvastatin 10–20mg/day (p=0.016) and pitavastatin 1–4mg/day (p=0.036) or with no statin treatment (p=0.018).

Conclusions

This study suggests that there are differences in the diabetogenic effect of statins. Simvastatin and high doses of atorvastatin may be associated with greater impairment in glucose metabolism than pitavastatin and other statins with less lipid-lowering potency such as pravastatin.

Keywords:
Statin
Diabetes
Diabetogenic effect
Prediabetes
Abnormal fasting glucose
Abbreviations:
BMI
CHD
FPG
HbA1c
HDL-C
LDL-C
MS
NODM
Non-HDL-C
SD
SEA
Resumen
Introducción

Las estatinas son utilizadas de acuerdo con el entendimiento de que el pequeño riesgo de incremento de diabetes se ve compensado por sus beneficios cardiovasculares. Sin embargo, puede resultar necesario reconsiderar si la terapia con estatinas incrementa realmente el riesgo, principalmente en la población con prediabetes.

Métodos

Se realizó un estudio multicéntrico, transversal y observacional para evaluar la relación entre la terapia con estatinas y el metabolismo de la glucosa en 407 pacientes de 63,1 años (11 DE) diagnosticados de dislipidemia y prediabetes tratados en clínicas especializadas en lípidos en España.

Resultados

Se encontraron diferencias significativas en los valores de HbA1c entre los grupos de tratamiento (p=0,015). Los pacientes tratados con pitavastatina (1-4mg/día) reflejaron los menores niveles de HbA1c, con diferencias significativas en comparación con los pacientes tratados con atorvastatina 40-80mg/día (p=0,016) y simvastatina 10-40mg/día (p=0,036). Por contra, los pacientes tratados con atorvastatina 40-80mg/día reflejaron los mayores niveles de HbA1c en comparación con los pacientes que recibieron atorvastatina 10-20mg/día (p=0,003), pitavastatina 1-4mg/día (p=0,016), pravastatina 20-40mg/día (p=0,027), rosuvastatina 5-10mg/día (p=0,043) y los que no recibieron estatinas (p=0,004). Los pacientes tratados con simvastatina 10-40mg/día tuvieron también valores más elevados que aquellos pacientes tratados con atorvastatina 10-20mg/día (p=0,016) y pitavastatina 1-4mg/día (p=0,036) que no recibieron estatinas (p=0,018).

Conclusiones

El presente estudio sugiere que existen diferencias en cuanto al efecto diabetógeno de las estatinas. Simvastatina y las altas dosis de atorvastatina pueden guardar relación con un mayor deterioro del metabolismo de la glucosa que pitavastatina y demás estatinas con menor potencia de reducción de lípidos, tales como pravastatina.

Palabras clave:
Estatinas
Diabetes
Diabetogenic effect
Prediabetes
Abnormal fasting glucose

Article

These are the options to access the full texts of the publication Medicina Clínica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcli.2018.08.003
No mostrar más